A groundbreaking DNA test developed by scientists from the University of Cambridge, in partnership with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, has the potential to revolutionise cancer treatment. Supported by Cancer Research UK, this test predicts whether cancer patients will respond to chemotherapy.

How It Works

The test examines chromosomal instability (CIN) signatures in a cancer’s DNA. These signatures reflect the order, structure, and number of DNA copies in cancer cells. By identifying these patterns, researchers can predict if a tumour will resist commonly used chemotherapy drugs like platinum-based, anthracycline, and taxane chemotherapies.

Why It Matters

 Chemotherapy can be life-saving, but it’s not effective for everyone. It also comes with severe side effects. This new test could help doctors avoid giving chemotherapy to patients unlikely to benefit from it. Instead, patients could receive more suitable and personalised treatments from the start.

Testing and Results

The test was piloted on 840 cancer patients and successfully identified those resistant to specific chemotherapy types. For example:

• Resistance to taxane led to higher failure rates in ovarian, metastatic breast, and prostate cancers.
• Resistance to anthracyclines showed poor outcomes in ovarian and breast cancers.
• Resistance to platinum chemotherapy led to greater failure in ovarian cancer cases.

Real-Life Impact

Fiona Barvé, a patient and cancer awareness advocate, supported the research. Diagnosed with ovarian cancer, she strongly believes personalised treatment could help patients avoid unnecessary suffering and improve recovery outcomes. Her involvement highlights how patient voices are shaping modern research.

Clinical Adoption and Next Steps

The research team used samples already collected during standard diagnosis, making the test easy to adopt in clinics. Now, the goal is to gain regulatory approval and expand the test’s use across different types of cancers and chemotherapy options.

The Bigger Vision

This innovation supports the mission of the Cambridge Cancer Research Hospital—a new facility under development that will bring together scientists and doctors to advance personalised medicine.

At The Doctorpreneur Academy, we’re committed to showcasing how emerging technologies are reshaping healthcare. From research to practice, breakthroughs like this test remind us of the importance of innovation and patient-centric care.

Call to Action:

Stay updated with the latest medical breakthroughs and healthcare innovations.

Visit The Doctorpreneur Academy to explore how technology is transforming patient outcomes.

👉 To register for our next masterclass, please click here https://linktr.ee/docpreneur